biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by Sniper007on Mar 27, 2014 4:31pm

140 Views

Post# 22378394

RE:RE:RE:Good news but...

I would say "annoyed" is putting it lightly JD. What a joke.

You bring up a lot of good points JD and I agree with you Sir_Holler (Where is the survival/efficacy data from last summer?). Maybe this conference is a precursor to the survival/efficacy piece? Not likely anytime soon given how long it's taken to see the 1st paper from TTU, or shall I say - HAVEN'T SEEN!!! Arggg.

BTI is doing very good things, no question, but they are often missing the bullseye, dropping the ball and not crossing the "T" and dotting the "I"s for "need to know" shareholders. Why is that happening BTI? Why?

Now that Medimmune is finished with the "first phase" of the collaboration, is it possible BTI has the resources now for another pharma, or two, to take on new collaborations? If there are indeed pharma's knocking at the door, could BTI not charge two pharmas 5 million each and then use the funds to take BT2111 to a phase 1 clinical trial? Thoughts? JD?

Frustrated.

Sniper

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario